SBI board approves ₹60,000 crore fund raise via debt instruments

State Bank of India's board has approved a proposal to raise ₹60,000 crore through debt instruments, including Basel III compliant Additional Tier 1 and Tier 2 bonds, during FY27. The fundraising will be conducted via public offer or private placement to Indian and overseas investors, subject to government approval where required. This move aims to bolster the bank's capital base to meet regulatory requirements and support business growth.

Fundraising Details

The board's decision encompasses a mix of long-term bonds and Basel III compliant instruments. The specific instruments approved include:

Long Term Bonds
Basel III compliant Additional Tier 1 Bonds
Basel III compliant Tier 2 Bonds

Funds will be raised in INR or any other convertible currency. The issuance is subject to necessary approvals from the Government of India.

Meeting Summary

The Central Board meeting held on June 18, 2026, commenced at 10:00 am and concluded at 1:15 pm. The approval was granted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Parameter	Details
Meeting Date	June 18, 2026
Total Fundraising Target	₹60,000 crore
Instruments	Long Term Bonds, Basel III AT1, Tier 2 Bonds
Mode	Public offer / Private placement
Tenure	FY27

State Bank of India has joined hands with Sun Pharmaceutical Industries to facilitate funding for a USD 1 billion deal in the United States, according to a report by Bloomberg. The development highlights a notable financial collaboration between a major Indian public sector lender and one of the country's prominent pharmaceutical companies.

Deal Overview

The key details available from the source are summarized below:

Parameter:	Details
Deal Value:	USD 1 billion
Parties Involved:	State Bank of India and Sun Pharmaceutical Industries
Market:	United States
Source:	Bloomberg

The partnership between State Bank of India and Sun Pharmaceutical Industries underscores the growing role of Indian financial institutions in supporting large-scale cross-border transactions by domestic corporates. The USD 1 billion deal reflects the scale of Sun Pharmaceutical Industries' strategic ambitions in the US market, with State Bank of India stepping in as a key funding partner.

No additional details regarding the specific structure of the funding arrangement, the nature of the underlying transaction, or the timeline for completion were available in the source data at this time.